Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.125 USD | +0.36% | +4.33% | +10.91% |
09/05 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.91% | 2.02Cr | |
+7.56% | 11TCr | |
+11.37% | 11TCr | |
-12.39% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.79% | 1.68TCr | |
+38.14% | 1.25TCr | |
-24.38% | 808.97Cr |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Pharmaceuticals Submits New Drug Application to FDA for Phase 1 Trial of DA-1726 for Obesity; Shares Rise